ARK Investment Management sells BWX Technologies and Strata Critical Medical to fund GeneDx and Arcturus Therapeutics purchases
ARK Investment Management adjusted its portfolio holdings across the ARKK, ARKG, and ARKQ ETFs on Thursday, April 9, 2026. The largest transaction of the day was the purchase of 32,767 shares of GeneDx Holdings Corp across the ARKK and ARKG ETFs, totaling approximately $2,149,187. ARK also acquired 3,447 shares of Arcturus Therapeutics Holdings Inc through its ARKG ETF for $29,299. These acquisitions were funded by the selling of 3,478 shares of BWX Technologies Inc through the ARKK and ARKQ ETFs for $806,130 and the sale of 57,744 shares of Stratat Critical Medical Inc through the ARKQ ETF for $238,482.
More Briefs
The One Big Beautiful Bill Act pushes average tax refunds to $3,521
Apr 12A three-month extension on margin rule compliance could prevent forced sell-offs in Bangladesh’s distressed market
Apr 12Fundstrat Predicts S&P 500 Target of 7,300 as Sector Repricing Limits Pullback Depth
Apr 12A rate cut is expected, but the data may force the ECB to hold